Rate My Professor Kjetil Tasken

Taskén's research specializations encompass immune regulation and cancer immunology, cancer precision medicine, cancer biology, cell signaling in health and disease, drug development, and translational medicine. His group studies tumor immune evasion mechanisms to boost anti-tumor immunity, regulatory T cell targets, cancer drug sensitivity screening in patient-derived cells for personalized therapies, and clinical implementation of precision cancer medicine through initiatives like IMPRESS-Norway. He has authored over 295 peer-reviewed articles, cited more than 14,000 times with an h-index of 63, including key publications such as Taskén & Mahon (2025) 'Accelerating precision oncology by converging pragmatic trials and real-world evidence' in Nature Reviews Drug Discovery; Tasken et al. (2024) 'PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe' in Acta Oncologica; and Diaz, Wei & Tasken (2023) 'Small molecule inhibitors targeting regulatory T cells for cancer treatment' in European Journal of Immunology. Taskén has received major awards including the UiO Innovation Prize (2023), King Olav V’s Prize for Cancer Research (2016), Anders Jahre Medical Award for Younger Scientists (2002), Faculty Medal from the UiO Faculty of Medicine (2018), and Digitalis Purpurea Award (2018). He has delivered over 300 lectures worldwide and contributes to advancing precision oncology in Norway and Europe.